Structure Therapeutics Inc.
Clinical-stage metabolic biotech developing oral small-molecule GPCR agonists, led by aleniglipron for obesity.
Obesity & metabolic disease · Structure-based oral small-molecule GPCR agonists · Phase 2 complete / Phase 3 planned Q3 2026